Mohamad N Shafiee1,2, Nigel Mongan3, Claire Seedhouse4, Caroline Chapman5, Suha Deen6, Jafaru Abu7, William Atiomo1. 1. Division of Obstetrics and Gynecology and Child Health, School of Medicine, Faculty of Medicine and Health Sciences, Queen's Medical Centre, Nottingham University Hospital, Nottingham, UK. 2. Faculty of Medicine, Department of Obstetrics and Gynecology, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. 3. School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK. 4. Department of Hematology, University of Nottingham, Nottingham, UK. 5. Division of Medical Sciences and Graduate Entry Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK. 6. Department of Pathology, Queen's Medical Centre, Nottingham University Hospital, Nottingham, UK. 7. Department of Obstetrics and Gynecology, City Hospital, Nottingham University Hospital, Nottingham, UK.
Abstract
INTRODUCTION: Women with polycystic ovary syndrome have a three-fold higher risk of endometrial cancer. Insulin resistance and hyperlipidemia may be pertinent factors in the pathogenesis of both conditions. The aim of this study was to investigate endometrial sterol regulatory element binding protein-1 gene expression in polycystic ovary syndrome and endometrial cancer endometrium, and to correlate endometrial sterol regulatory element binding protein-1 gene expression with serum lipid profiles. MATERIAL AND METHODS: A cross-sectional study was performed at Nottingham University Hospital, UK. A total of 102 women (polycystic ovary syndrome, endometrial cancer and controls; 34 participants in each group) were recruited. Clinical and biochemical assessments were performed before endometrial biopsies were obtained from all participants. Taqman real-time polymerase chain reaction for endometrial sterol regulatory element binding protein-1 gene and its systemic protein expression were analyzed. RESULTS: The body mass indices of women with polycystic ovary syndrome (29.28 ± 2.91 kg/m2 ) and controls (28.58 ± 2.62 kg/m2 ) were not significantly different. Women with endometrial cancer had a higher mean body mass index (32.22 ± 5.70 kg/m2 ). Sterol regulatory element binding protein-1 gene expression was significantly increased in polycystic ovary syndrome and endometrial cancer endometrium compared with controls (p < 0.0001). Sterol regulatory element binding protein-1 gene expression was positively correlated with body mass index (r = 0.017, p = 0.921) and waist-hip ratio (r = 0.023, p = 0.544) in polycystic ovary syndrome, but this was not statistically significant. Similarly, statistically insignificant positive correlations were found between endometrial sterol regulatory element binding protein-1 gene expression and body mass index in endometrial cancer (r = 0.643, p = 0.06) and waist-hip ratio (r = 0.096, p = 0.073). Sterol regulatory element binding protein-1 gene expression was significantly positively correlated with triglyceride in both polycystic ovary syndrome and endometrial cancer (p = 0.028 and p = 0.027, respectively). Quantitative serum sterol regulatory element binding protein-1 gene correlated with endometrial gene expression (p < 0.05). CONCLUSIONS: Sterol regulatory element binding protein-1 gene expression is significantly increased in the endometrium of women with polycystic ovary syndrome and women with endometrial cancer compared with controls and positively correlates with serum triglyceride in both polycystic ovary syndrome and endometrial cancer.
INTRODUCTION:Women with polycystic ovary syndrome have a three-fold higher risk of endometrial cancer. Insulin resistance and hyperlipidemia may be pertinent factors in the pathogenesis of both conditions. The aim of this study was to investigate endometrial sterol regulatory element binding protein-1 gene expression in polycystic ovary syndrome and endometrial cancer endometrium, and to correlate endometrial sterol regulatory element binding protein-1 gene expression with serum lipid profiles. MATERIAL AND METHODS: A cross-sectional study was performed at Nottingham University Hospital, UK. A total of 102 women (polycystic ovary syndrome, endometrial cancer and controls; 34 participants in each group) were recruited. Clinical and biochemical assessments were performed before endometrial biopsies were obtained from all participants. Taqman real-time polymerase chain reaction for endometrial sterol regulatory element binding protein-1 gene and its systemic protein expression were analyzed. RESULTS: The body mass indices of women with polycystic ovary syndrome (29.28 ± 2.91 kg/m2 ) and controls (28.58 ± 2.62 kg/m2 ) were not significantly different. Women with endometrial cancer had a higher mean body mass index (32.22 ± 5.70 kg/m2 ). Sterol regulatory element binding protein-1 gene expression was significantly increased in polycystic ovary syndrome and endometrial cancer endometrium compared with controls (p < 0.0001). Sterol regulatory element binding protein-1 gene expression was positively correlated with body mass index (r = 0.017, p = 0.921) and waist-hip ratio (r = 0.023, p = 0.544) in polycystic ovary syndrome, but this was not statistically significant. Similarly, statistically insignificant positive correlations were found between endometrial sterol regulatory element binding protein-1 gene expression and body mass index in endometrial cancer (r = 0.643, p = 0.06) and waist-hip ratio (r = 0.096, p = 0.073). Sterol regulatory element binding protein-1 gene expression was significantly positively correlated with triglyceride in both polycystic ovary syndrome and endometrial cancer (p = 0.028 and p = 0.027, respectively). Quantitative serum sterol regulatory element binding protein-1 gene correlated with endometrial gene expression (p < 0.05). CONCLUSIONS:Sterol regulatory element binding protein-1 gene expression is significantly increased in the endometrium of women with polycystic ovary syndrome and women with endometrial cancer compared with controls and positively correlates with serum triglyceride in both polycystic ovary syndrome and endometrial cancer.
Authors: William Atiomo; Mohamad Nasir Shafiee; Caroline Chapman; Veronika M Metzler; Jad Abouzeid; Ayşe Latif; Amy Chadwick; Sarah Kitson; Vanitha N Sivalingam; Ian J Stratford; Catrin S Rutland; Jenny L Persson; Niels Ødum; Pablo Fuentes-Utrilla; Jennie N Jeyapalan; David M Heery; Emma J Crosbie; Nigel P Mongan Journal: Clin Endocrinol (Oxf) Date: 2017-08-18 Impact factor: 3.478
Authors: Mohamad Nasir Shafiee; Catharine A Ortori; David A Barrett; Nigel P Mongan; Jafaru Abu; William Atiomo Journal: Int J Mol Sci Date: 2020-07-03 Impact factor: 5.923
Authors: Verónica Yumiceba; Andrés López-Cortés; Andy Pérez-Villa; Iván Yumiseba; Santiago Guerrero; Jennyfer M García-Cárdenas; Isaac Armendáriz-Castillo; Patricia Guevara-Ramírez; Paola E Leone; Ana Karina Zambrano; César Paz-Y-Miño Journal: Front Endocrinol (Lausanne) Date: 2020-10-26 Impact factor: 5.555